Bone and fat cross-talk in antiretroviral therapy (ART) treated HIV patients

抗逆转录病毒疗法 (ART) 治疗的 HIV 患者的骨和脂肪交叉对话

基本信息

  • 批准号:
    10548410
  • 负责人:
  • 金额:
    $ 41.78万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-01 至 2027-07-31
  • 项目状态:
    未结题

项目摘要

Project Summary / Abstract The widespread use of combination antiretroviral therapy (cART) has significantly increased the lifespan of people living with HIV (PLWH). As HIV has become a chronic disease, there is a growing concern of the disproportionate risk of a variety of comorbidities. Two such comorbidities that occur at a higher prevalence in cART treated PLWH include bone loss and fat gain. Interestingly, as new treatment recommendations have shifted to cART regimens that are less bone toxic, there appears to be an increased prevalence of excessive fat gain and an increased risk for the development of metabolic syndrome. Our long-term goal is to determine the mechanisms contributing to these comorbid conditions in cART treated PLWH in order to find less deleterious treatment options. The current proposal will test the central hypothesis that the hormonal communication between bone and fat explains how antiretrovirals (ARVs) contribute to bone loss and fat gain in PLWH. Our hypothesis is based on our preliminary data showing hormonal changes in response to ARVs and correlations between the changes in bone and fat hormones and BMD loss and fat gain with cART initiation. To test our hypothesis, we propose to take a hierarchical approach that will include in vitro, preclinical, and human subject studies. In Aim 1, we will define the contribution of individual ARVs and cART to bone and fat cellular function and hormonal production using primary human cells. In Aim 2, we will investigate the skeletal and metabolic response to individual ARVs and cART using both an uninfected wild-type mouse and a humanized mouse model of HIV-infection. Finally, in Aim 3, we will determine the association between bone and fat-derived hormones and bone mass and body composition in three critical treatment stages, cART initiation, long-term stable cART treatment, and switching cART regimens. If successful, this proposal, submitted by an early stage investigator (ESI), will provide significant insights into key comorbidities faced by HIV patients on cART—specifically by illuminating how individual ARVs negatively affect bone/fat cell function and hormonal production. At the same time, this proposal will increase our general understanding of the bone- fat hormonal axis.
项目总结/摘要 联合抗逆转录病毒疗法(cART)的广泛使用显著增加了 艾滋病毒感染者(PLWH)。由于艾滋病毒已成为一种慢性疾病, 多种合并症的不成比例风险。两种这样的合并症,发生率较高, cART治疗的PLWH包括骨丢失和脂肪增加。有趣的是,随着新的治疗建议 转向骨毒性较小的cART方案后,过度使用抗逆转录病毒药物的患病率似乎有所增加 脂肪增加和代谢综合征风险增加。我们的长期目标是确定 在接受cART治疗的PLWH中导致这些共病状况的机制, 有害的治疗选择。目前的建议将测试中心假设,即激素 骨和脂肪之间的沟通解释了抗逆转录病毒药物(ARV)如何导致骨丢失和脂肪增加 在PLWH。我们的假设是基于我们的初步数据显示激素变化的反应,抗逆转录病毒药物 以及骨和脂肪激素变化与骨密度降低和脂肪增加与cART的相关性 入会仪式为了验证我们的假设,我们建议采取分层方法,包括体外, 临床前和人类受试者研究。在目标1中,我们将定义单个抗逆转录病毒药物和cART对 骨和脂肪细胞功能以及使用原代人类细胞产生激素。在目标2中,我们将研究 使用未感染的野生型小鼠, 和HIV感染的人源化小鼠模型。最后,在目标3中,我们将确定 在三个关键治疗阶段,cART中的骨和脂肪源性激素以及骨量和身体成分 启动、长期稳定的cART治疗和转换cART方案。如果成功的话,这个提议, 由早期研究者(ESI)提交,将为以下患者面临的关键合并症提供重要见解: 通过阐明个体抗逆转录病毒药物如何对骨/脂肪细胞功能产生负面影响, 和荷尔蒙分泌同时,这一建议将增加我们对骨骼的普遍了解- 脂肪激素轴

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Ryan Dee Ross其他文献

Ryan Dee Ross的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Ryan Dee Ross', 18)}}的其他基金

Identifying the long-term metabolic complications of in-utero and lactational antiretroviral exposure
确定子宫内和哺乳期抗逆转录病毒暴露的长期代谢并发症
  • 批准号:
    10762179
  • 财政年份:
    2023
  • 资助金额:
    $ 41.78万
  • 项目类别:
Bone and fat cross-talk in antiretroviral therapy (ART) treated HIV patients
抗逆转录病毒疗法 (ART) 治疗的 HIV 患者的骨和脂肪交叉对话
  • 批准号:
    10856307
  • 财政年份:
    2022
  • 资助金额:
    $ 41.78万
  • 项目类别:
Assessing the function role of sclerostin in periodontal disease in XLH
评估硬化素在 XLH 牙周病中的功能作用
  • 批准号:
    10303753
  • 财政年份:
    2021
  • 资助金额:
    $ 41.78万
  • 项目类别:
Characterization of a humanized mouse model to study HIV and ARV effects on bone
研究 HIV 和 ARV 对骨骼影响的人源化小鼠模型的表征
  • 批准号:
    10324198
  • 财政年份:
    2021
  • 资助金额:
    $ 41.78万
  • 项目类别:
Assessing the function role of sclerostin in periodontal disease in XLH
评估硬化素在 XLH 牙周病中的功能作用
  • 批准号:
    10454382
  • 财政年份:
    2021
  • 资助金额:
    $ 41.78万
  • 项目类别:
Sclerostin Regulation of Skeletal Mineralization and Phosphate Metabolism
硬化素对骨骼矿化和磷酸盐代谢的调节
  • 批准号:
    10457434
  • 财政年份:
    2019
  • 资助金额:
    $ 41.78万
  • 项目类别:
Sclerostin Regulation of Skeletal Mineralization and Phosphate Metabolism
硬化素对骨骼矿化和磷酸盐代谢的调节
  • 批准号:
    10240577
  • 财政年份:
    2019
  • 资助金额:
    $ 41.78万
  • 项目类别:

相似国自然基金

相似海外基金

New development of cellular regeneration therapy in jaw bone using stem cells derived from adipocytes jaw bone
利用颌骨脂肪细胞来源的干细胞进行颌骨细胞再生治疗的新进展
  • 批准号:
    23K16058
  • 财政年份:
    2023
  • 资助金额:
    $ 41.78万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
A novel mechanism of insulin resistance mediated by uric acid metabolism in adipocytes
脂肪细胞尿酸代谢介导胰岛素抵抗的新机制
  • 批准号:
    23K10969
  • 财政年份:
    2023
  • 资助金额:
    $ 41.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Hypertrophic adipocytes as biophysical mediators of breast cancer progression
肥大脂肪细胞作为乳腺癌进展的生物物理介质
  • 批准号:
    10751284
  • 财政年份:
    2023
  • 资助金额:
    $ 41.78万
  • 项目类别:
Elucidation of mechanisms for conversion of adipocytes to cancer-associated fibroblasts in osteosarcoma microenvironment
阐明骨肉瘤微环境中脂肪细胞转化为癌症相关成纤维细胞的机制
  • 批准号:
    23K19518
  • 财政年份:
    2023
  • 资助金额:
    $ 41.78万
  • 项目类别:
    Grant-in-Aid for Research Activity Start-up
Study on UCP-1 independent metabolic regulation by brown adipocytes
棕色脂肪细胞对UCP-1独立代谢调节的研究
  • 批准号:
    23K18303
  • 财政年份:
    2023
  • 资助金额:
    $ 41.78万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Development of adipocytes for gene therapy that avoids cellular stress due to overexpression of therapeutic proteins
开发用于基因治疗的脂肪细胞,避免因治疗蛋白过度表达而造成的细胞应激
  • 批准号:
    23H03065
  • 财政年份:
    2023
  • 资助金额:
    $ 41.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Functional analysis of bitter taste receptors in adipocytes and hepatocytes
脂肪细胞和肝细胞中苦味受体的功能分析
  • 批准号:
    23K05107
  • 财政年份:
    2023
  • 资助金额:
    $ 41.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
NKA/CD36 signaling in adipocytes promotes oxidative stress and drives chronic inflammation in atherosclerosis
脂肪细胞中的 NKA/CD36 信号传导促进氧化应激并驱动动脉粥样硬化的慢性炎症
  • 批准号:
    10655793
  • 财政年份:
    2023
  • 资助金额:
    $ 41.78万
  • 项目类别:
The mechanisms of the signal transduction from brown adipocytes to afferent neurons and its significance.
棕色脂肪细胞向传入神经元的信号转导机制及其意义。
  • 批准号:
    23K05594
  • 财政年份:
    2023
  • 资助金额:
    $ 41.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Characterizing breast cancer invasion and proliferation when co-aggregated with adipocytes in multicellular spheroids created with a custom bioreactor to augment cell-cell connectivity.
当与多细胞球体中的脂肪细胞共聚集时,表征乳腺癌的侵袭和增殖,该多细胞球体是用定制生物反应器创建的,以增强细胞间的连接。
  • 批准号:
    10334113
  • 财政年份:
    2022
  • 资助金额:
    $ 41.78万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了